Curaleaf Holdings (CURLF) Depreciation & Amortization (CF) (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Depreciation & Amortization (CF) of $73.1 million for Q4 2024, up 42.3% year-over-year from $51.4 million in Q1 2024, and up 33.88% quarter-over-quarter from $54.6 million in Q3 2024.
Curaleaf Holdings (CURLF) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $73.1 million for Q4 2024.
- In Q4 2024, Depreciation & Amortization (CF) rose 42.3% year-over-year to $73.1 million; the TTM figure through Sep 2025 stood at $73.1 million (down 31.02% YoY), while the FY2025 annual figure was $196.6 million, down 15.06% from the prior year.
- Depreciation & Amortization (CF) for Q4 2024 stood at $73.1 million, up from $54.6 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $73.1 million in Q4 2024, with the low at $14.9 million in Q1 2020.
- The 5-year median for Depreciation & Amortization (CF) is $33.7 million (2021), against an average of $36.4 million.
- The sharpest annual moves came in 2021 and 2022: Depreciation & Amortization (CF) jumped 86.24% in 2021, then fell 19.13% in 2022.
- Curaleaf Holdings' Depreciation & Amortization (CF) stood at $20.2 million in 2020, then gained by 25.47% to $25.4 million in 2021, then jumped by 73.66% to $44.1 million in 2022, then rose by 16.55% to $51.4 million in 2023, then jumped by 42.3% to $73.1 million in 2024.
- Business Quant data shows CURLF's Depreciation & Amortization (CF) at $73.1 million in Q4 2024, $54.6 million in Q3 2024, and $51.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | 48.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.61 Mn |
| Jun 30, 2026 | 48.61 Mn |
| Jun 30, 2025 | 49.16 Mn |
| Jun 30, 2025 | 49.16 Mn |
| Dec 31, 2024 | 73.12 Mn |
| Dec 31, 2024 | 73.12 Mn |
| Sep 30, 2024 | 54.61 Mn |
| Sep 30, 2024 | 54.61 Mn |
| Dec 31, 2023 | 51.38 Mn |
| Dec 31, 2023 | 51.38 Mn |
| Sep 30, 2023 | 47.28 Mn |
| Sep 30, 2023 | 47.28 Mn |
| Dec 31, 2022 | 44.09 Mn |
| Dec 31, 2022 | 44.09 Mn |
| Sep 30, 2022 | 28.23 Mn |
| Sep 30, 2022 | 28.23 Mn |
| Jun 30, 2022 | 42.82 Mn |
| Jun 30, 2022 | 42.82 Mn |
| Mar 31, 2022 | 40.84 Mn |
| Mar 31, 2022 | 40.84 Mn |